T

hree US senators want the US Department of Justice to investigate whether Mylan Pharmaceuticals violated federal law with its classification of its EpiPen device with the Medicaid Drug Rebate Program. Under the program, companies are responsible for accurately reporting and paying a rebate on drugs paid for by Medicaid.

In a letter to US Attorney General Loretta Lynch, the senators contend that Mylan may have violated the False Claims Act by “knowingly” misclassifying EpiPen as a generic instead of a brand-name product. A violation occurs when a company “knowingly conceals or knowingly and improperly avoids or decreases an obligation to pay . . . money . . . to the government,” they wrote.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • “And why did it take so long to notice this disparity?” Sorry – just a rhetorical question … I will bet that Medicare Part D did not require an automatic reclassification of existing generic products. Any takers?

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.